佛慈制药：间接控股股东甘肃省国有资产投资集团有限公司承诺在收购完成后五年内解决同业竞争问题

Group 1 - The core point of the article is that Foci Pharmaceutical (002644) has received a commitment from its indirect controlling shareholder, Gansu State-owned Assets Investment Group Co., Ltd., to resolve the issue of competition within the same industry within five years after the acquisition is completed [1] - As of now, this commitment has not yet expired, indicating that the company is actively monitoring the situation [1] - The company has stated that it will fulfill its obligation for information disclosure in a timely manner if there are any updates regarding this matter [1]